文献速递消化道肿瘤放疗

局部晚期食管癌最佳放疗剂量:随机临床试验重建个体患者数据的汇总分析

Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.
PubMed 文献 · Radiother Oncol · 2025-03-22

该汇总分析纳入6项随机临床试验共1722例患者,比较高剂量放疗(≥59.4 Gy)与标准剂量放疗(50 Gy/50.4 Gy)在根治性同步放化疗中的疗效。结果显示高剂量放疗在3年总生存、无进展生存和局部区域无进展生存方面均无显著获益,但≥3级治疗相关不良事件发生率更高。结论支持当前指南采用标准剂量放疗的临床实践。

要点

  • 高剂量放疗与标准剂量放疗相比,3年总生存无显著差异(RR=1.00,P=0.990)。
  • 高剂量放疗组≥3级治疗相关不良事件发生率更高(OR=1.26,P=0.025)。
  • 亚组分析显示即使在亚组中,剂量递增也未带来长期生存获益。

核心结论

  • 高剂量放疗相比标准剂量放疗在3年总生存、无进展生存和局部区域无进展生存方面均无显著获益,且≥3级治疗相关不良事件发生率更高。
  • 结果支持当前指南采用标准剂量放疗的临床实践,并为探索新型药物联合(如免疫治疗)而非放疗剂量递增的可行性提供启示。

研究设计与样本

  • 基于个体患者数据的Meta分析,纳入比较High-dose radiotherapy(HD-RT,≥59.4 Gy)与Standard-dose radiotherapy(SD-RT,50 Gy/50.4 Gy)的随机临床试验。
  • 共纳入6项随机临床试验,1722例患者;总生存、无进展生存和局部区域无进展生存的个体患者数据分别来自1287、462和722例患者。
  • 采用图形重建算法从原始随机临床试验的Kaplan-Meier曲线中提取时间至事件结局,并采用固定或随机效应模型汇总报告的风险比。

主要发现

  • 高剂量放疗组与标准剂量放疗组相比,3年总生存无显著差异(RR=1.00,P=0.990)。
  • 高剂量放疗组与标准剂量放疗组相比,3年无进展生存无显著差异(RR=0.96,P=0.320)。
  • 高剂量放疗组与标准剂量放疗组相比,3年局部区域无进展生存无显著差异(RR=0.88,P=0.204)。
  • 高剂量放疗对比标准剂量放疗的总生存、无进展生存和局部区域无进展生存的汇总风险比分别为0.99(P=0.854)、0.94(P=0.628)和0.91(P=0.410)。
  • 高剂量放疗组≥3级治疗相关不良事件发生率高于标准剂量放疗组(OR=1.26,P=0.025)。

临床怎么用

  • 作者结论认为结果支持当前指南和采用标准剂量放疗的临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal radiation dose of definitive concurrent chemoradiotherapy (dCCRT) for esophageal cancer (EC) has always been a concern in radiation oncology and has remained controversial for several decades, we performed a meta-analysis based on individual patient data (IPD) to explore the optimal dose. METHODS: Randomized clinical trials (RCTs) comparing high-dose radiotherapy (HD-RT,≥59.4 Gy) with standard-dose radiotherapy (SD-RT, 50 Gy/50.4 Gy) were identified. Graphical reconstructive algorithms were employed to extract time-to-event outcomes from Kaplan-Meier curves presented in the original RCTs. Using reconstructed individual patient data, summary overall survival (OS), progression-free survival (PFS) and locoregional progression-free survival (LRPFS) for HD-RT versus SD-RT were recalculated. Hazard Ratios (HRs) of OS, PFS and LRPFS reported were also pooled by the fixed or random effects model. RESULTS: Six RCTs, including 1722 patients, were included. IPD for OS, PFS, and LRPFS were from 1287, 462, and 722 patients, respectively. Overall, HD-RT had no significant benefits in 3-year OS (RR = 1.00, P = 0.990), 3-year progression-free survival (PFS) (RR = 0.96, P = 0.320) and 3-year locoregional progression-free survival (LRPFS) (RR = 0.88, P = 0.204), compared with SD-RT. Consistent with above results, the pooled HRs of OS, PFS and LRPFS for HD-RT versus SD-RT were 0.99 (P = 0.854), 0.94 (P = 0.628) and 0.91 (P = 0.410), respectively. However, HD-RT had higher grade ≥ 3 treatment-related adverse effects (TRAEs) (OR = 1.26, P = 0.025). Subgroup analyses were also performed based on the RT techniques, histology, size of the RT target, dose-escalation mode, and stage editions. We found that dose escalation, even in subgroups, did not benefit long-term survival but resulted in a higher incidence of grade ≥ 3 TRAEs. CONCLUSION: The results provide robust evidence that corroborates current guidelines and supports the clinical practice of employing SD-RT. Additionally, it provides implications for the feasibility of further research into novel drug combinations (e.g., immunotherapy) rather than radiation dose escalation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Li R, Wang X, Luo J, et al. Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials. Radiother Oncol. 2025. PMID: 40122283. doi:10.1016/j.radonc.2025.110867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。